CytoSorbents' Product Associated With High Survival In Critically Ill COVID-19 Patients

  • CytoSorbents Corporation CTSO has announced topline results from its CytoSorb Therapy in COVID-19 (CTC) multicenter registry.
  • The data were presented at the International Symposium on Intensive Care and Emergency Medicine.
  • The CTC Registry included 52 consecutive critically ill COVID-19 patients with refractory acute respiratory distress syndrome (ARDS) on life support with ECMO and CytoSorb.
  • The primary outcome of 90-day ICU mortality was 27% in the CTC Registry, below the 50% in the North American cohort of the international Extracorporeal Life Support Organization (ELSO) Registry in over 4,600 patients.
  • Rates of ICU discharge and recovery exceeded ICU mortality rates throughout the follow-up period. All patients discharged alive from the ICU also survived to hospital discharge.
  • CytoSorb treatment led to a decrease in elevated baseline inflammatory biomarkers.
  • Also Read: CytoSorbents' Antithrombotic Removal System Scores Second FDA Breakthrough Device Tag.
  • Price Action: CTSO shares are up 4.08% at $9.96 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLong IdeasNewsSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!